Table of Contents
Ulcers
Volume 2011 (2011), Article ID 156407, 7 pages
http://dx.doi.org/10.1155/2011/156407
Research Article

Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

1Laboratory of Gastroenterology, Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway
2Department of Medical Gastroenterology, University Hospital of North Norway, 9037 Tromsø, Norway

Received 16 September 2010; Revised 3 December 2010; Accepted 14 December 2010

Academic Editor: Kazunari Tominaga

Copyright © 2011 J. Florholmen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Bouma and W. Strober, “The immunological and genetic basis of inflammatory bowel disease,” Nature Reviews Immunology, vol. 3, no. 7, pp. 521–533, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. I. J. Fuss, M. Neurath, and M. Neurath, “Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's sisease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5,” Journal of Immunology, vol. 157, no. 3, pp. 1261–1270, 1996. View at Google Scholar · View at Scopus
  3. F. Heller, P. Florian, and P. Florian, “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution,” Gastroenterology, vol. 129, no. 2, pp. 550–564, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. Mayer, “Evolving paradigms in the pathogenesis of IBD,” Journal of Gastroenterology, vol. 45, no. 1, pp. 9–16, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. B. Sartor, “Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 3, no. 7, pp. 390–407, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. Dionne, J. Hiscott, I. D'Agata, A. Duhaime, and E. G. Seidman, “Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies,” Digestive Diseases and Sciences, vol. 42, no. 7, pp. 1557–1566, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Stallmach, T. Giese, C. Schmidt, B. Ludwig, I. Mueller-Molaian, and S. C. Meuer, “Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease,” International Journal of Colorectal Disease, vol. 19, no. 4, pp. 308–315, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. McCormack, D. Moriarty, D. P. O'Donoghue, P. A. McCormick, K. Sheahan, and A. W. Baird, “Tissue cytokine and chemokine expression in inflammatory bowel disease,” Inflammation Research, vol. 50, no. 10, pp. 491–495, 2001. View at Google Scholar · View at Scopus
  9. G. Y. Melmed and M. T. Abreu, “New insights into the pathogenesis of inflammatory bowel disease,” Current Gastroenterology Reports, vol. 6, no. 6, pp. 474–481, 2004. View at Google Scholar · View at Scopus
  10. T. Olsen, R. Goll, G. Cui, A. Husebekk, B. Vonen, G. S. Birketvedt, and J. Florholmen, “Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis,” Scandinavian Journal of Gastroenterology, vol. 42, no. 11, pp. 1312–1320, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Akazawa, I. Sakaida, S. Higaki, Y. Kubo, K. Uchida, and K. Okita, “Increased expression of tumor necrosis factor-α messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase,” Journal of Gastroenterology, vol. 37, no. 5, pp. 345–353, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. F. Casellas, M. Papo, F. Guarner, M. Antolin, J. R. Armengol, and J. R. Malgelada, “Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis,” Clinical Science, vol. 87, no. 4, pp. 453–458, 1994. View at Google Scholar · View at Scopus
  13. G. Järnerot, E. Hertervig, and E. Hertervig, “Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study,” Gastroenterology, vol. 128, no. 7, pp. 1805–1811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Rutgeerts, W. J. Sandborn, and W. J. Sandborn, “Infliximab for induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2462–2476, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. T. Olsen, G. Cui, R. Goll, A. Husebekk, and J. Florholmen, “Infliximab therapy decreases the levels of TNF-α and IFN-γ mRNA in colonic mucosa of ulcerative colitis,” Scandinavian Journal of Gastroenterology, vol. 44, no. 6, pp. 727–735, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. Olsen, J. Goll, G. Cui, I. Christiansen, and J. Florholmen, “Tissue expressions of TNF-alpha in colorectal mucosa as a predictor of clinical outcome from induction therapy with infliximab in ulcerative colitis,” Cytokine, vol. 46, pp. 222–227, 2009. View at Google Scholar
  17. S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; preliminary report on a therapeutic trial,” British medical journal, vol. 2, no. 4884, pp. 375–378, 1954. View at Google Scholar · View at Scopus
  18. S. C. Ng and M. A. Kamm, “Therapeutic strategies for the management of ulcerative colitis,” Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 935–950, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. B. E. Sands, “From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation,” Gastroenterology, vol. 126, no. 6, pp. 1518–1532, 2004. View at Publisher · View at Google Scholar
  20. P. Marteau, C. S. Probert, and C. S. Probert, “Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study,” Gut, vol. 54, no. 7, pp. 960–965, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. L. R. Sutherland, F. Martin, and S. Greer, “5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis,” Gastroenterology, vol. 92, no. 6, pp. 1894–1898, 1987. View at Google Scholar
  22. P. Rutgeerts, W. J. Sandborn, and W. J. Sandborn, “Infliximab for induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2462–2476, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. S. C. Lindgren, L. M. Flood, A. F. Kilander, R. Löfberg, T. B. Persson, and R. I. Sjödahl, “Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis,” European Journal of Gastroenterology and Hepatology, vol. 10, no. 10, pp. 831–835, 1998. View at Google Scholar
  24. C. Su, J. D. Lewis, B. Goldberg, C. Brensinger, and G. R. Lichtenstein, “A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis,” Gastroenterology, vol. 132, no. 2, pp. 516–526, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. W. A. Faubion, E. V. Loftus, W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, “The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study,” Gastroenterology, vol. 121, no. 2, pp. 255–260, 2001. View at Google Scholar
  26. A. Kohn, C. Prantera, A. Pera, R. Cosintino, R. Sostegni, and M. Daperno, “Infliximab in the treatment of severe ulcerative colitis: a follow-up study,” European Review for Medical and Pharmacological Sciences, vol. 8, no. 5, pp. 235–237, 2004. View at Google Scholar
  27. J. P. Gisbert, Y. González-Lama, and J. Maté, “Systematic review: infliximab therapy in ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 1, pp. 19–37, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. S. Campbell, S. Travis, and D. Jewell, “Ciclosporin use in acute ulcerative colitis: a long-term experience,” European Journal of Gastroenterology and Hepatology, vol. 17, no. 1, pp. 79–84, 2005. View at Publisher · View at Google Scholar
  29. G. Van Assche, S. Vermeire, and P. Rutgeerts, “Immunosuppression in inflammatory bowel disease: traditional, biological or both?” Current Opinion in Gastroenterology, vol. 25, no. 4, pp. 323–328, 2009. View at Publisher · View at Google Scholar · View at PubMed